Clinical Policy: Olaratumab (Lartruvo)
Reference Number: CP.PHAR.326
Effective Date: 03.01.17
Last Review Date: 02.21
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Olaratumab (Lartruvo®) is a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody.

FDA Approved Indication(s)
Lartruvo is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.

Limitation(s) of use: This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.

*Eli Lilly and Co, manufacturer of Lartruvo, was issued a letter revoking the approval to manufacture and market Lartruvo (see Appendix E).

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Lartruvo is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Soft Tissue Sarcoma (must meet all):
      1. Authorization is not permitted. Member may not initiate therapy with Lartruvo. If member is currently using Lartruvo proceed to section II. A. Soft Tissue Sarcoma for continued therapy criteria (see Appendix E).

   Approval duration: Not applicable

   B. Other diagnoses/indications
      1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid.
II. Continued Therapy
   A. Soft Tissue Sarcoma (must meet all):
      1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Lartruvo for a covered indication and has received this medication for at least 30 days;
      2. Member is responding positively to therapy;
      3. Patient has not had disease progression on Lartruvo;
      4. If request is for a dose increase, request meets one of the following (a or b):
         a. New dose does not exceed 15 mg/kg on Days 1 and 8 of each 21-day cycle;
         b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
   Approval duration: 12 months

   B. Other diagnoses/indications (must meet 1 or 2):
      1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
         Approval duration: Duration of request or 6 months (whichever is less);
      2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   FDA: Food and Drug Administration
   NCCN: National Comprehensive Cancer Network
   PDGFR-α: platelet-derived growth factor receptor alpha
   STS: soft tissue sarcoma

   Appendix B: Therapeutic Alternatives
   This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>doxorubicin HCL (Adriamycin®)</td>
<td>Labeled dosing regimen for metastatic STS:</td>
<td>Varies</td>
</tr>
<tr>
<td></td>
<td>• As a single agent: 60 to 75 mg/m² IV every 21 days.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• In combination with other chemotherapy drugs: 40 to 75 mg/m²2 IV every 21 to 28 days.</td>
<td></td>
</tr>
</tbody>
</table>
### Drug Name | Dosing Regimen | Dose Limit/Maximum Dose
---|---|---
| | • Consider use of the lower doxorubicin dose in the recommended dose range or longer intervals between cycles for heavily pretreated patients, elderly patients, or obese patients. • Cumulative doses above 550 mg/m² are associated with an increased risk of cardiomyopathy. | |

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

**Appendix C: Contraindications/Black Box Warnings**
None reported

**Appendix D: STS Subtypes**
- Sarcomas are divided into STS and sarcomas of bone.
- More than 50 STS histologic subtypes have been identified. Common subtypes include undifferentiated sarcoma, gastrointestinal stromal tumor, liposarcoma, and leiomyosarcoma.
- The most common anatomic STS locations are extremities, trunk, visceral, retroperitoneum, and head and neck. Rhabdomyosarcoma is the most common STS of children and adolescents and is less common in adults.

**Appendix E: ANNOUNCE Trial: NCCN and FDA update**
- NCCN no longer recommends Lartruvo in combination with doxorubicin as a treatment option for:
  - Soft tissue sarcoma subtypes with non-specific histologies (soft tissue sarcoma [version 2.2019]). The following language has been deleted from the guideline: For use in STS histologies for which an anthracycline-containing regimen is appropriate.
  - Uterine sarcoma (uterine neoplasms [version 3.2019])
- January 18, 2019, Eli Lilly reported in a press release that the confirmatory study required as a condition of Lartruvo’s accelerated approval, entitled “Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma” (ANNOUNCE trial), “did not meet the primary endpoints of overall survival in the full study population or in the leiomyosarcoma subpopulation.”
- January 24th, 2019 updated: In light of this information, the FDA recommends that patients who are currently receiving Lartruvo should consult with their healthcare provider about whether to remain on the treatment. The FDA also recommends that Lartruvo should not be initiated in new patients outside of an investigational study.
- September 27, 2019, Eli Lilly requested withdrawal (revocation), in writing, of the BLA for Lartruvo (BLA 761038) because the ANNOUNCE trial failed to demonstrate improvement in overall survival for olaratumab in combination with doxorubicin
compared to doxorubicin alone. In that letter, Eli Lilly waived its opportunity for a hearing.

- On February 25, 2020, the FDA issued a letter to Eli Lilly revoking the approval to manufacture and market Lartruvo.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>STS</td>
<td>15 mg/kg IV over 60 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity. For first 8 cycles, Lartruvo is administered with doxorubicin. Refer to doxorubicin prescribing information for dosing, and dose modifications.</td>
<td>15 mg/kg per infusion</td>
</tr>
</tbody>
</table>

VI. Product Availability

Single-dose vial: 500 mg/50 mL, 190 mg/19 mL

VII. References


**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J9285</td>
<td>Injection, olaratumab, 10 mg</td>
</tr>
</tbody>
</table>
Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy split from CP.PHAR.182 Excellus Oncology. NCCN off-label recommended uses added.</td>
<td>02.17</td>
<td>03.17</td>
</tr>
<tr>
<td>Policy converted to new template. Safety criteria was applied according to the safety guidance discussed at CPAC and endorsed by Centene Medical Affairs. Added criteria for NCCN 2A and above recommended off-label use: Uterine sarcoma. Authorization limits extended from 3 and 6 months to 6 and 12 months for initial and continued approval, respectively.</td>
<td>08.30.17</td>
<td>11.17</td>
</tr>
<tr>
<td>4Q 2018 annual review: no significant changes; NCCN and FDA-approved uses summarized for improved clarity; specialist involvement in care and continuation of care added; references reviewed and updated.</td>
<td>08.07.18</td>
<td>11.18</td>
</tr>
<tr>
<td>4Q 2019 annual review: removed uterine sarcoma from criteria; updated Appendix D to state NCCN guidelines’ removal of doxorubicin and olaratumab as a combination therapy for STS and uterine sarcoma; references reviewed and updated.</td>
<td>08.09.19</td>
<td>11.19</td>
</tr>
<tr>
<td>4Q 2020 annual review: modified HIM-Medical Benefit to HIM line of business; no significant changes; references reviewed and updated.</td>
<td>08.17.20</td>
<td>11.20</td>
</tr>
<tr>
<td>Added Commercial line of business; removed initial approval criteria for soft tissue sarcoma; added criteria to continuation approval for soft tissue sarcoma requiring patient has not had disease progression on Lartruvo; added Appendix E: FDA update due to ANNOUNCE trial results; references to HIM.PHAR.21 revised to HIM.PA.154; references reviewed and updated.</td>
<td>11.10.20</td>
<td>02.21</td>
</tr>
</tbody>
</table>

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and
limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.